Press Releases

Loxo Oncology Announces Closing of Initial Public Offering and Partial Exercise of Over-Allotment Option

STAMFORD, Conn., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today announced the closing of the initial public offering of 5,903,538 shares of its common stock, including 642,000 shares of common stock that were issued upon the exercise of the underwriters' over-allotment option to purchase additional shares, at a price to the public of $13.00 per share. The initial closing of 5,261,538 shares of common stock occurred on August 6, 2014. Concurrently with the initial closing, Loxo Oncology also sold through a private placement 230,769 shares of its common stock to New Enterprise Associates 14, L.P., an existing stockholder, at the initial public offering price.

Cowen and Company, LLC and Stifel acted as joint book-running managers for the offering. JMP Securities LLC and Oppenheimer & Co. Inc. acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on July 31, 2014.

The offering is being made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (631) 274-2806 or by fax at (631) 254-7140; or from Stifel, Nicolaus & Company, Inc., Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: syndicateops@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACTS: 

Jacob S. Van Naarden
Vice President, Corporate Development and Strategy
jake@loxooncology.com

Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com
Loxo Oncology